Thonzylamine

Identification

Name
Thonzylamine
Accession Number
DB11235
Description

Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with Clofedanol or Phenylephrine for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 286.379
Monoisotopic: 286.179361344
Chemical Formula
C16H22N4O
Synonyms
  • neohetramine
  • Thonzylamine

Pharmacology

Indication

Thozylamine is indicated for use in the symptomatic control of allergic rhinitis or other upper respiratory allergic symptoms Label. It is typically a part of combination over the counter products.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Thonzylamine is a first-generation antihistamine. It antagonizes the action of histamine to relief allergic symptoms like nasal congestion, runny nose, itchy eyes, itchy nose and throat, and sneezing Label,1

Mechanism of action

Thonzylamine competes with histamine for binding to the H1 histamine receptor 1. Binding of histamine to this receptor stimulates vasodilation and increased vascular permeability leading to nasal congestion and runny nose 3. Histamine also produces itchiness by stimulating nerve endings which can result in sneezing. By blocking these effects, thonzylamine can reduce or eliminate symptoms of allergic rhinitis.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Humans
UMuscarinic acetylcholine receptor M1
antagonist
Humans
UMuscarinic acetylcholine receptor M2
antagonist
Humans
UMuscarinic acetylcholine receptor M3
antagonist
Humans
UMuscarinic acetylcholine receptor M4
antagonist
Humans
UMuscarinic acetylcholine receptor M5
antagonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Doses of up to 300 mg/day for up to 4 days have produces no observable toxic effects in humans 2. In a chronic toxicity study, rats were given up to 200 mg/kg/day orally for 91 days with no observable toxic effects 1.

Affected organisms
Not Available
Pathways
PathwayCategory
Thonzylamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
AclidiniumThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Thonzylamine.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thonzylamine.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Thonzylamine.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
AlosetronAlosetron may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Thonzylamine hydrochloride6K9YKD48Y463-56-9HRYJPHOTGFERGT-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Nasopen PEThonzylamine hydrochloride (50 mg/15mL) + Phenylephrine hydrochloride (10 mg/15mL)LiquidOralGM Pharmaceuticals, INC2012-10-03Not applicableUS flag
Poly Hist PDThonzylamine hydrochloride (6.25 mg/1mL) + Chlophedianol hydrochloride (6.25 mg/1mL)LiquidOralPoly Pharmaceuticals, Inc.2013-07-01Not applicableUS flag
Poly-Hist DMThonzylamine hydrochloride (25 mg/5mL) + Dextromethorphan hydrobromide monohydrate (10 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL)LiquidOralPoly Pharmaceuticals, Inc.2013-06-22Not applicableUS flag
TexaClear Kids Sinus ReliefThonzylamine hydrochloride (50 mg/30mL) + Phenylephrine hydrochloride (5 mg/30mL)LiquidOralGM Pharmaceuticals, INC2015-06-152019-01-16US flag
Vanacof ApeThonzylamine hydrochloride (50 mg/15mL) + Chlophedianol hydrochloride (25 mg/15mL) + Phenylephrine hydrochloride (10 mg/15mL)LiquidOralGm Pharmaceuticals2012-10-032014-09-30US flag

Categories

ATC Codes
D04AA01 — ThonzylamineR06AC06 — ThonzylamineR01AC06 — Thonzylamine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Anisoles
Direct Parent
Anisoles
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Benzylamines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Alkyl aryl ether / Amine / Aminopyrimidine / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzylamine / Dialkylarylamine / Ether / Heteroaromatic compound
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
R79646H5Z8
CAS number
91-85-0
InChI Key
GULNIHOSWFYMRN-UHFFFAOYSA-N
InChI
InChI=1S/C16H22N4O/c1-19(2)11-12-20(16-17-9-4-10-18-16)13-14-5-7-15(21-3)8-6-14/h4-10H,11-13H2,1-3H3
IUPAC Name
N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyrimidin-2-amine
SMILES
COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1

References

General References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
  3. Chapter 39: Histamine, Bradykinin, and Their Antagonists. (2018). In Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. [ISBN:978-1-25-958473-2]
Human Metabolome Database
HMDB0240222
PubChem Compound
5457
PubChem Substance
347827947
ChemSpider
5258
RxNav
1360721
ChEBI
104017
ChEMBL
CHEMBL1623738
ZINC
ZINC000000057513
Wikipedia
Thonzylamine
FDA label
Download (190 KB)
MSDS
Download (82.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)173-176Scudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99.
water solubilityHighly SolubleScudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99.
Predicted Properties
PropertyValueSource
Water Solubility0.733 mg/mLALOGPS
logP2.4ALOGPS
logP2.42ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity86.19 m3·mol-1ChemAxon
Polarizability32.42 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-05fr-9720000000-8a7d4d036feab1e4ee54
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
  2. AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]

Drug created on December 03, 2015 09:51 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates